---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-086254"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2026-07-23T20:05:20+00:00"
generated_at: "2026-07-23T20:06:11.530813+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics receives Nasdaq extension to Jan 19, 2027 to regain $1 minimum bid price compliance

## Summary
- Received Nasdaq notification on July 23, 2026 granting additional 180-day compliance period until Jan 19, 2027.
- Must achieve closing bid price of $1.00 for 10 consecutive business days during extension.
- If not compliant by Jan 19, 2027, Nasdaq will issue delisting notice; company may appeal.
- Previously reported deficiency notice on Jan 23, 2026; initial 180-day period expired July 22, 2026.

## SEC filing metadata
- accession: 0001104659-26-086254
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2026-07-23T20:05:20+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/0001104659-26-086254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465926086254/tm2621205d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-086254
- JSON: https://secwatch.observer/filing/0001104659-26-086254.json
- Plain text: https://secwatch.observer/filing/0001104659-26-086254.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.